Thirdly, the synergy between targeted drugs and PD-(L)1 inhibitors may impede tumor angiogenesis, promote vascular normalization, and overcome resistance to FOLFOX agents (31, 39, 40), thereby disrupting tumor hypoxia and enhancing drug delivery and permeation. This evidence concerns the gene CD274 and neoplasm.